Teligent, Inc. (NASDAQ:TLGT) issued its quarterly earnings data on Tuesday. The company reported ($0.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by $0.04, Morningstar.com reports. Teligent had a positive return on equity of 5.43% and a negative net margin of 14.35%. The company had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $20.11 million. During the same quarter last year, the business earned $0.02 earnings per share. The business’s quarterly revenue was up 7.4% on a year-over-year basis.

Teligent (NASDAQ:TLGT) opened at 7.02 on Wednesday. The company’s market cap is $373.65 million. The firm’s 50 day moving average is $8.60 and its 200-day moving average is $8.00. Teligent has a 52 week low of $5.75 and a 52 week high of $9.54.

A number of brokerages have weighed in on TLGT. Canaccord Genuity reaffirmed a “buy” rating and set a $11.00 target price on shares of Teligent in a research note on Tuesday. BidaskClub downgraded shares of Teligent from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Zacks Investment Research downgraded shares of Teligent from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. ValuEngine downgraded shares of Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $9.00 target price (up previously from $8.00) on shares of Teligent in a research note on Monday, July 17th. Three analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $9.50.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/teligent-inc-nasdaqtlgt-posts-quarterly-earnings-results-misses-estimates-by-0-04-eps.html.

A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. bought a new position in Teligent during the second quarter valued at about $619,000. State of Wisconsin Investment Board bought a new position in Teligent during the second quarter valued at about $284,000. Rhumbline Advisers increased its position in Teligent by 0.4% in the second quarter. Rhumbline Advisers now owns 49,622 shares of the company’s stock valued at $454,000 after buying an additional 200 shares during the last quarter. Eagle Global Advisors LLC increased its position in Teligent by 17.7% in the second quarter. Eagle Global Advisors LLC now owns 46,520 shares of the company’s stock valued at $426,000 after buying an additional 7,010 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC increased its position in Teligent by 240.5% in the second quarter. Campbell & CO Investment Adviser LLC now owns 38,543 shares of the company’s stock valued at $353,000 after buying an additional 27,222 shares during the last quarter. 62.75% of the stock is currently owned by institutional investors and hedge funds.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Earnings History for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.